10:55 AM EDT, 06/17/2025 (MT Newswires) -- Knight Therapeutics ( KHTRF ) on Tuesday said it has completed the acquisition of the Paladin business from Endo and separately said it has closed a US$50 million credit facility with National Bank of Canada (NBC).

On the Endo buy, Knight paid $107 million in cash including $22.3 million for inventory. The payment at closing was reduced by a holdback amount of $15.4 million, of which $10 million may be released under specific conditions and the remaining $5.4 million is expected to be used to settle certain liabilities. Knight may also pay future contingent payments of up to US$15 million upon achieving certain sales milestones.

Earlier this month, Knight sealed a deal to market certain Sumitomo Pharmaceuticals products in Canada. The company also acquired some Sumitomo mature products.

On the revolving credit facility, Knight has withdrawn C$60 million from it to fund part of the Paladin acquisition. It said the credit facility provides it with an initial borrowing limit of up to US$50 million, which is mainly intended to support the company's growth strategy and may also be used for working capital and other corporate purposes.

The facility, which is secured, has an initial term of three years, which can be extended annually by additional one-year terms. It is expected that the facility will be increased to US$100 million plus an accordion of US$50 million within the next six months.

The company's shares were last seen up $0.14, to $6.16 on the Toronto Stock Exchange.

Price: 6.12, Change: +0.10, Percent Change: +1.66